90Y-Radiopharmaceutical
90Y radiopharmaceuticals are therapeutic agents that utilize the yttrium-90 isotope, widely applied in targeted cancer treatment. Alfa Cytology specializes in the research and development of 90Y radiopharmaceuticals, offering comprehensive solutions to aid in precise patient treatment.
Introduction to 90Y-Radiopharmaceutical
90Y radiopharmaceuticals are therapeutic drugs based on the yttrium-90 isotope, primarily used for the targeted treatment of certain cancers. 90Y emits high-energy beta particles and has a half-life of approximately 2.67 days, allowing for efficient therapeutic dosing in vivo. By conjugating 90Y with antibodies, ligands, or other carriers, it can precisely target cancer-specific markers for tumor-directed therapy. The primary advantage of this approach is its ability to concentrate radiation energy on cancer cells, minimizing collateral damage to healthy tissues.
Fig 1. Yttrium-90 ibritumomab tiuxetan. (ALHAJ MOUSTAFA M, et al., 2023)
Key Features of 90Y Radiopharmaceuticals
- Beta-Particle Radiation: 90Y emits high-energy β particles that effectively kill cancer cells within a short range (1-2 mm), ideal for localized tumor treatment.
- Optimal Half-Life: Its 2.67-day half-life ensures effective radiation delivery while minimizing long-term effects on nearby healthy tissues.
- Precise Targeting: 90Y's ability to bind with targeting molecules like antibodies allows for precise tumor targeting, enhancing treatment efficacy and preserving healthy tissues.
- Reduced Radiation Hazard: Without significant gamma radiation, 90Y reduces radiation exposure to the surrounding environment during treatment.
Our Services
Alfa Cytology is committed to developing innovative 90Y radiopharmaceuticals, aiming to deliver precise oncology treatments by integrating targeted molecular technology with the radioisotope yttrium-90. Our 90Y radiopharmaceutical development service covers the entire spectrum from drug design and synthesis to preclinical evaluation, ensuring both efficacy and safety of the therapeutic agents.
Workflow of 90Y-Radiopharmaceutical Development
Target Molecule Selection and Design
Identify and design molecules suitable for binding with the radioisotope yttrium-90 (90Y), such as antibodies, single-chain antibodies (scFv), peptides, and nanoparticles, which can specifically target tumor cells or diseased tissues.
Radiopharmaceutical Synthesis
Label 90Y isotopes with target molecules (e.g., antibodies, peptides) through chemical reactions. This involves introducing the 90Y isotope to a specific site on the target molecule, like the Fc region of an antibody or a designated site on a peptide. Utilize metal ligands such as DOTA or NOTA to efficiently bind yttrium-90, ensuring in vivo stability.
Radiopharmaceutical Stability and Quality Control
Assess the stability of 90Y radiopharmaceuticals under various storage conditions to ensure they remain stable and avoid isotope decay or release during treatment. Evaluate the stability in both solution and solid dosage forms to maintain drug quality throughout preparation, transport, and usage.
Preclinical Studies
Investigate drug accumulation in tumor tissues, its half-life, and the ability of the targeted drug to act on tumors in a sustained and effective manner. This includes pharmacokinetic (PK) studies, assessment of targeting characteristics, and toxicology evaluations.
Alfa Cytology is a leading expert in the field of 90Y radiopharmaceutical development, dedicated to advancing cancer treatment through innovative solutions. We offer a comprehensive suite of customized services, ranging from initial target molecule design to thorough preclinical evaluation, all aimed at enhancing precision oncology treatments. For more detailed information about our pioneering 90Y radiopharmaceutical development services, please feel free to contact us.
Reference
- ALHAJ MOUSTAFA M, BORAH B J, MORIARTY J P, et al. Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas [J]. Clinical lymphoma, myeloma & leukemia, 2023, 23(4): 259-65.
For research use only. Not intended for any clinical use.
Related Service
